glp-1 news today 2025 november Who Gets the Shot? Access by State GLP-1 weight loss drugs are
Description
The half-life of semaglutide was comparable between healthy subjects and individuals with type 2 diabetes
See if you qualify today: Disclosure: Eligibility and results may vary
While oral semaglutide produces meaningful weight loss, injectable formulations consistently outperform, and more patients discontinue oral semaglutide due to gastrointestinal side effects
Discontinuation rates
The most pronounced reduction in bariatric procedures occurred in 2020 (-17.7%), followed by relative stabilization in 2021 (-3.5%) and 2022 (-0.7%), before declining further in 2023 (-10.1%)
